Journal
EXPERT REVIEW OF MEDICAL DEVICES
Volume 1, Issue 1, Pages 21-31Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/17434440.1.1.21
Keywords
bioengineered tissue; chronic wound; dermal fibroblast; diabetic foot ulcer; wound healing
Categories
Ask authors/readers for more resources
Chronic nonhealing diabetic foot ulcers are a common medical problem that may precede severe complications such as Infection, sepsis and limb loss. Current standard methods of treatment are aimed at removing necrotic debris, controlling infection, and relieving chronic pressure on the wound. Unfortunately, healing rates are poor with standard treatment, averaging 12-20 weeks In clinical trials. A new strategy for the treatment of diabetic foot ulcers has been developed through tissue engineering, allowing the application of healthy living skin cells to assist In the healing process. It Is hoped that the living tissue will release appropriate quantifies of growth factors, cytokines and other proteins to stimulate the chronic wound bed and accelerate healing. Dermagraff (R) (Smith & Nephew) Is a neonatal-derived bioengineered tissue comprised of dermal fibroblasts. In this article, the structure and behavior of this tissue will be examined, focusing particularly on the randomized clinical trials performed to justify Its use in diabetic foot ulcers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available